In veterinary inhalation anesthesia, anaesthetic ether is filled as a stabilised liquid active pharmaceutical ingredient rather than incorporated into a tablet, capsule, granule, premix, or injection. The finished dosage form is a volatile liquid intended for precision vaporizer delivery or calibrated open-drop administration. Pharmacopoeial compliance is evaluated against the USP-NF Ether monograph and the Ph. Eur. anaesthetic ether monograph; residual solvent and purity testing uses Ph. Eur. 5.4 and USP-NF <467> only when qualifying the supplied material as an excipient-free API. The only intentional formulation additive is butylated hydroxytoluene, added at 2–5 ppm w/w as a peroxide-chain-breaker; water is controlled to ≤0.2% w/w because dissolved water accelerates peroxide accumulation and glass container corrosion. Production filling is governed by ATEX 2014/34/EU and NFPA 30, with continuous lower-explosive-limit monitoring; diethyl ether LEL is 1.9% v/v, so nitrogen inerting and static grounding are maintained throughout the line. Downstream processing uses stainless steel or glass-lined receivers, 0.2 μm PTFE membrane filtration, and automated crimp sealing under inert gas. Terminal product types are 100 mL, 200 mL, and 500 mL veterinary vaporizer refill bottles, plus sealed ampoules for short-term field anesthesia use. Published production-scale batch records for specific veterinary anaesthetic ether terminal filling are limited; each filling site must validate peroxide evolution under light and temperature stress.

What limits the lower explosive level of ether in veterinary tablet granulation?

High-shear granulation of moisture-sensitive veterinary tablet blends can use diethyl ether as a rapidly evaporating granulation fluid. The operating constraint is not the solvent's boiling point alone—34.6 °C—but the lower explosive level of 1.9% v/v, which requires exhaust ether concentration to remain below 25% LEL, equivalent to 0.475% v/v. Addition ratios in production-scale trials range from 5–15% w/w on dry powder mass, using a high-shear mixer with impeller tip speed 2–6 m/s and chopper speed 1000–2500 rpm. The wet mass is transferred to a fluid-bed dryer with inlet air at 25–35 °C and dew point below -20 °C; exhaust gas passes to solvent recovery or thermal oxidation. Compliance of the finished solid dosage form is assessed under ICH Q3C Class 3 and USP-NF <467> residual solvents; ether is a Class 3 solvent with a permitted daily exposure of 50 mg/day, corresponding to a concentration limit of 5000 ppm. Process qualification uses headspace GC-FID according to USP-NF <467> Procedure A. Equipment must comply with ATEX 2014/34/EU category 2G for Zone 1 volumes, and nitrogen dilution is used to keep oxygen below 5% v/v during drying. Terminal product types include film-coated veterinary tablets, hard gelatin capsule powders, and granulated premix intermediates. Ether is not recommended in formulations containing amine-functional polymers or strongly oxidisable excipients; peroxide interaction can cause premature granule discoloration and assay loss.

In low-dose capsule manufacture, diethyl ether is not introduced as a capsule filler but as a low-temperature deposition solvent for moisture-sensitive APIs onto pre-gelatinised starch or microcrystalline cellulose carriers. The solvent addition is set at 3–8% w/w of carrier mass, mixed in low-shear tumble equipment until a solvent-moistened mass with loss-on-drying 8–12% is obtained; vacuum drying at ≤40 °C then removes ether below the ICH Q3C Class 3 concentration limit of 5000 ppm. Residual solvent release follows USP-NF <467> headspace GC with flame ionisation detection. Because the boiling point of ether is 34.6 °C, the dryer is purged with nitrogen and oxygen is maintained below 5% v/v; static bonding and conductive flooring are also applied under ATEX 2014/34/EU. The resulting powder blends display improved flow and content uniformity and are filled into hard gelatin capsules; terminal product types include multi-component veterinary antibiotic capsules and water-soluble powder sachets. This route is considered established practice only for products with tight residual solvent specifications; process air must not be recirculated until verified as free of peroxides.

When ether is deployed as an enveloped-virus inactivation solvent in killed veterinary vaccine production

Cold-phase ether treatment is used in the manufacture of killed viral veterinary vaccines to inactivate lipid-enveloped viruses while preserving antigenic surface proteins. Compliance is evaluated under VICH GL18 for viral safety of veterinary medicinal products and under Ph. Eur. 5.2.5 where applicable; process records must demonstrate strain-specific inactivation kinetics, lot-to-lot consistency, and residual solvent elimination. The addition ratio is typically 10–20% v/v diethyl ether to clarified antigen suspension at 4–8 °C, with continuous mixing for 16–24 h; published production-scale data for specific veterinary antigen configurations is limited, so factorial validation at small scale is a prerequisite. After temperature-controlled phase separation, the aqueous antigen layer is subjected to nitrogen sparging or thin-film evaporation to reduce residual ether below 5000 ppm. Flammability control requires ATEX 2014/34/EU equipment, continuous LEL monitoring at 1.9% v/v lower explosive limit, and inertisation with nitrogen to keep oxygen below 5% v/v. Terminal product types include adjuvanted injectable killed viral vaccines, lyophilized vaccine powders for reconstitution, and intranasal inactivated vaccine solutions. Contact surfaces are specified as stainless steel or glass-lined, and elastomer seals must be polytetrafluoroethylene or ethylene propylene diene monomer; nitrile rubber swells in ether and is excluded from the inactivation vessel.

Diethyl ether functions as a cold antisolvent in the purification of thermolabile veterinary drug substances intended for sterile injectable formulation. The concentrated feed solution is held in a polar aprotic or alcoholic solvent, and ether is added at an antisolvent ratio of 3:1 to 10:1 v/v with jacket temperature maintained between -5 °C and +5 °C. Linear antisolvent addition over 30–90 min and post-addition ageing for 2–4 h control nucleation; where available, focused beam reflectance measurement is used to track chord length distribution. After vacuum filtration, the wet cake is washed with cold ether and dried in a rotary vacuum dryer at ≤30 °C. Residual solvent limits follow ICH Q3C Option 2 for Class 3 solvents, not more than 0.5% w/w in the drug substance, and the final injectable dosage form must meet USP-NF <467>. Terminal product types are sterile injectable suspensions and lyophilized injectable powders. Published data for specific veterinary active substances in this particular ether-antisolvent configuration is limited; every crystallisation must be validated for polymorphic consistency, residual solvent, and particle size distribution. Explosion protection during antisolvent addition includes ATEX 2014/34/EU rated vessels, nitrogen blanketing, and control of static discharge through bonded mixing blades and grounded filter housings.

Solvent-assisted layering of anaesthetic ether in veterinary premix and powder formulations

Ether is applied as a volatile deposition solvent in veterinary premix and in-feed powder production when heat-labile active substances cannot be layered by aqueous spray granulation. The solvent is delivered at 5–25% w/w relative to the pre-sieved carrier mass—typically limestone, silica, or corn cob fraction—through binary nozzles into a fluid-bed coater or vacuum coating pan. Jacket temperature is held at 20–30 °C to leverage the 34.6 °C boiling point of ether, while exhaust vapour is routed to condensation or thermal oxidation. Residual solvent in the finished premix must not exceed 5000 ppm under ICH Q3C Class 3; in EU feed additive formulations, the authorisation conditions of Regulation (EC) 1831/2003 also apply. Terminal product types include medicated feed premixes, water-soluble powders, and granular in-feed formulations. Equipment is rated under ATEX 2014/34/EU; nitrogen inerting maintains oxygen below 5% v/v, and exhaust LEL monitoring is maintained at ≤25% LEL (0.475% v/v). Ether layering should not be used for methionine-rich or highly unsaturated carrier systems due to elevated peroxide sensitivity; published data for specific heat-labile veterinary actives on feed carriers is limited and requires pilot-scale qualification.